通讯作者: 杨莉, lyang@bjmu.edu.cn

DOI：10.12201/bmr.202203.00008

Influencing factors analysis on price reduction in national volume-based drug procurement.

• 摘要：目的：分析国家组织药品集中带量采购过程中生产企业是否中选及中选价格影响因素，探讨带量采购政策效果及是否仍有提升空间。方法：选取第二批-第五批药品集中带量采购涉及品种进行分析，以中选企业是否中选以及价格降幅为因变量，企业特征和竞争因素相关指标为自变量，采用Heckman两阶段模型分析药品价格降幅及是否中选的影响因素并控制潜在的选择偏倚。结果：原研企业相较于仿制药企业中选概率更低，但是一旦中选其价格降幅相较于仿制药企业高41%；市场份额较小企业相较于原有市场份额较高企业(>50%)中选概率更大，但价格降幅低7%；具备原料药生产加工资质的企业更易中选，但是价格降幅相较于不具备相关资质企业没有显著差异；潜在竞争者数量每增加1%，企业中选概率更低，中选价格降幅增加0.26个百分点。结论：药品带量采购可以有效促进原研药产生“专利悬崖”现象，理顺药品价格形成机制。具备原料药生产加工资质的企业体现出更强的成本控制能力。同时，仍可以进一步突出具备原料药生产加工资质企业在国家集采中的重要性以及制定动态触发机制，这有利于保障供应以及进一步运用市场机制降低药品价格。

  关键词： 带量采购; 价格; 影响因素

   

  Abstract: Objectives: To analyze the influencing factors on price reduction in national volume-based procurement (NVBP) in China, so as to investigate the effect of NVBP and probable improvements. Methods: The results from the 2nd-5th rounds of NVBP were selected in analysis. Bidding results including the prices reduction and bid winner were selected as dependent variables. Company characteristics and competition status were chosen as independent variables. A Heckman two stage model was conducted for potential selection bias. Results: Manufactures of brand drugs are less likely to become bid-winner but their price reduction is 41% higher than manufactures of generics. Companies with higher market share (>50%) are less likely to win the bids compare with companies with less (0-50%) or zero share of market. Besides, the price reduction of companies with less market share are 7% fewer than other companies. Manufactures with ability to extract active pharmaceutical ingredients from raw materials are more likely to win but no difference in price reduction was observed. When potential competitors in group increased by 1%, the price reduction increased by 0.26 percentage and companies are less likely to win. Conclusion: VBP program can effectively promote the appearance of “patent cliff” in China and rationalize the pricing mechanism of drugs. However, more importance could be attached to ability of extracting active pharmaceutical ingredients and establishment of dynamic trigger mechanism, which could further improve the supply security and lowering the prices under market mechanism.

  Key words: volume-based procurement; price; influencing factors

  提交时间：2022-03-21

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 曾叙衡, 郑颐, 吕军, 宁玉玲, 励晓红. 实施高值医用耗材带量采购的SWOT分析——以上海市为例. 2020. doi: 10.12201/bmr.202010.00841

  宋佳, 范成鑫, 王婉晨, 艾旭峰, 刘馨璐, 李翠玉, 张玉杰, 李秋莎, 王安琪, 丰志强, 尹文强, 马东平. 利益相关者视角下我国药品集中带量采购政策研究——基于政策工具的文本分析. 2022. doi: 10.12201/bmr.202203.00006

  董程诚, 熊巨洋. 慢性病管理信息系统使用意愿影响因素研究. 2020. doi: 10.12201/bmr.202006.00002

  李钊, 赵珂, 周绿林, 陈盛. 国家集采常态化视域下药品集团采购模式对比及发展对策研究. 2021. doi: 10.12201/bmr.202109.00037

  峗怡. 欧洲国家健康水平的关键影响因素分析 —基于欧洲36国的定性比较分析（QCA）. 2020. doi: 10.12201/bmr.202006.00006

  崔蓓, 王磊. 基于ISM的我国生物医药创新能力影响因素分析. 2022. doi: 10.12201/bmr.202111.00015

  郭沙沙, 沈立岩, 王权, 姚璐, 甄雪梅, 孙强. 基于模糊集的村医抗生素不合理使用影响因素的定性比较分析*. 2021. doi: 10.12201/bmr.202106.00018

  陈荃, 雷行云, 高星, 胡红濮. 基于行为理论的老年糖尿病患者移动健康干预策略构建研究. 2020. doi: 10.12201/bmr.202005.00245

  董婷婷. 医疗人工智能产品对患者安全的影响及对策研究. 2020. doi: 10.12201/bmr.202012.00004

  虢毅, 龚李越, 胡德华. 基于整合模型的在线健康社区用户持续使用意愿的影响因素研究. 2021. doi: 10.12201/bmr.202110.00041

• 序号	提交日期	编号	操作
  1	2022-01-24	bmr.202203.00008V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论